^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BRG01

    i
    Other names: BRG01
    Company:
    Biosyngen
    Drug class:
    T-cell stimulant
    Related drugs:
    8ms
    A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P1, N=14, Completed, BioSyngen Pte Ltd | Trial completion date: Jan 2028 --> Apr 2024 | Trial primary completion date: Jan 2028 --> Apr 2024 | Not yet recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    BRG01
    over1year
    A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, BioSyngen Pte Ltd
    New P1 trial • Metastases
    |
    BRG01